Abstract

Declining bone mass is associated with aging and osteoporosis, a disease characterized by progressive weakening of the skeleton and increased fracture incidence. Growth and lifelong homeostasis of bone rely on interactions between different cell types including vascular cells and mesenchymal stromal cells (MSCs). As these interactions involve Notch signaling, we have explored whether treatment with secreted Notch ligand proteins can enhance osteogenesis in adult mice. We show that a bone-targeting, high affinity version of the ligand Delta-like 4, termed Dll4(E12), induces bone formation in male mice without causing adverse effects in other organs, which are known to rely on intact Notch signaling. Due to lower bone surface and thereby reduced retention of Dll4(E12), the same approach failed to promote osteogenesis in female and ovariectomized mice but strongly enhanced trabecular bone formation in combination with parathyroid hormone. Single cell analysis of stromal cells indicates that Dll4(E12) primarily acts on MSCs and has comparably minor effects on osteoblasts, endothelial cells or chondrocytes. We propose that activation of Notch signaling by bone-targeted fusion proteins might be therapeutically useful and can avoid detrimental effects in Notch-dependent processes in other organs.

Data availability

scRNA-seq data have been deposited in the GEO functional genomics data repository under the accession number GSE152285. Data can be accessed via https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152285 with the token mzcbwwqgptidxmh.

The following data sets were generated

Article and author information

Author details

  1. Cong Xu

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Van Vuong Dinh

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Kai Kruse

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Hyun-Woo Jeong

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Emma C Watson

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0986-5524
  6. Susanne Adams

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Frank Berkenfeld

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Martin Stehling

    Flow Cytometry Unit, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Seyed Javad Rasouli

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Rui Fan

    Embryonic Self-Organization Research Group, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Rui Chen

    Embryonic Self-Organization Research Group, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Ivan Bedzhov

    Embryonic Self-Organization Research Group, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Qi Chen

    CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and Health, Guangzhou, China
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8485-6540
  14. Katsuhiro Kato

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Mara Elena Pitulescu

    Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    For correspondence
    mara.pitulescu@mpi-muenster.mpg.de
    Competing interests
    The authors declare that no competing interests exist.
  16. Ralf H Adams

    Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
    For correspondence
    ralf.adams@mpi-muenster.mpg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3031-7677

Funding

Max Planck Society

  • Ralf H Adams

European Research Council (AdG 339409 AngioBone)

  • Ralf H Adams

European Research Council (AdG 786672 PROVEC)

  • Ralf H Adams

Leducq Foundation

  • Ralf H Adams

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animals were housed at the Max Planck Institute for Molecular Biomedicine and protocols were approved by animal ethics committees with permissions (Az 81-02.04.2019.A114 and Az 81-02.04.2020.A416) granted by the Landesamt für Natur, Umwelt und Verbraucherschutz (LANUV) of North Rhine-Westphalia. Every effort was made to minimize suffering.

Copyright

© 2022, Xu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,290
    views
  • 424
    downloads
  • 24
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Cong Xu
  2. Van Vuong Dinh
  3. Kai Kruse
  4. Hyun-Woo Jeong
  5. Emma C Watson
  6. Susanne Adams
  7. Frank Berkenfeld
  8. Martin Stehling
  9. Seyed Javad Rasouli
  10. Rui Fan
  11. Rui Chen
  12. Ivan Bedzhov
  13. Qi Chen
  14. Katsuhiro Kato
  15. Mara Elena Pitulescu
  16. Ralf H Adams
(2022)
Induction of osteogenesis by bone-targeted Notch activation
eLife 11:e60183.
https://doi.org/10.7554/eLife.60183

Share this article

https://doi.org/10.7554/eLife.60183

Further reading

    1. Stem Cells and Regenerative Medicine
    Mami Matsuo-Takasaki, Sho Kambayashi ... Yohei Hayashi
    Tools and Resources

    Human induced pluripotent stem cells (hiPSCs) are promising resources for producing various types of tissues in regenerative medicine; however, the improvement in a scalable culture system that can precisely control the cellular status of hiPSCs is needed. Utilizing suspension culture without microcarriers or special materials allows for massive production, automation, cost-effectiveness, and safety assurance in industrialized regenerative medicine. Here, we found that hiPSCs cultured in suspension conditions with continuous agitation without microcarriers or extracellular matrix components were more prone to spontaneous differentiation than those cultured in conventional adherent conditions. Adding PKCβ and Wnt signaling pathway inhibitors in the suspension conditions suppressed the spontaneous differentiation of hiPSCs into ectoderm and mesendoderm, respectively. In these conditions, we successfully completed the culture processes of hiPSCs, including the generation of hiPSCs from peripheral blood mononuclear cells with the expansion of bulk population and single-cell sorted clones, long-term culture with robust self-renewal characteristics, single-cell cloning, direct cryopreservation from suspension culture and their successful recovery, and efficient mass production of a clinical-grade hiPSC line. Our results demonstrate that precise control of the cellular status in suspension culture conditions paves the way for their stable and automated clinical application.

    1. Stem Cells and Regenerative Medicine
    Wenxin Ma, Lian Zhao ... Wei Li
    Research Article

    Microglia exhibit both maladaptive and adaptive roles in the pathogenesis of neurodegenerative diseases and have emerged as a cellular target for central nervous system (CNS) disorders, including those affecting the retina. Replacing maladaptive microglia, such as those impacted by aging or over-activation, with exogenous microglia that can enable adaptive functions has been proposed as a potential therapeutic strategy for neurodegenerative diseases. To investigate microglia replacement as an approach for retinal diseases, we first employed a protocol to efficiently generate human-induced pluripotent stem cell (hiPSC)-derived microglia in quantities sufficient for in vivo transplantation. These cells demonstrated expression of microglia-enriched genes and showed typical microglial functions such as LPS-induced responses and phagocytosis. We then performed xenotransplantation of these hiPSC-derived microglia into the subretinal space of adult mice whose endogenous retinal microglia have been pharmacologically depleted. Long-term analysis post-transplantation demonstrated that transplanted hiPSC-derived microglia successfully integrated into the neuroretina as ramified cells, occupying positions previously filled by the endogenous microglia and expressed microglia homeostatic markers such as P2ry12 and Tmem119. Furthermore, these cells were found juxtaposed alongside residual endogenous murine microglia for up to 8 months in the retina, indicating their ability to establish a stable homeostatic state in vivo. Following retinal pigment epithelial cell injury, transplanted microglia demonstrated responses typical of endogenous microglia, including migration, proliferation, and phagocytosis. Our findings indicate the feasibility of microglial transplantation and integration in the retina and suggest that modulating microglia through replacement may be a therapeutic strategy for treating neurodegenerative retinal diseases.